Lisa H. Butterfield
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)University of Pittsburgh(US)University of California, San Francisco(US)Applied Science Laboratories (United States)(US)Parker Institute for Cancer Immunotherapy(US)UPMC Hillman Cancer Center(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune cells in cancer, Immune Cell Function and Interaction
Most-Cited Works
- → Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial(2017)1,375 cited
- → Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma(2010)559 cited
- → Immunotherapy of cancer in 2012(2012)431 cited
- → Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma(2015)382 cited
- → Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade(2017)357 cited
- → Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma